Investigator Roles and Responsibilities in Clinical Device Trials
|
|
- Sarah Carr
- 5 years ago
- Views:
Transcription
1 Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and Translational Education and Research Li Ka Shing Center for Learning and Knowledge September 28-29, 2010
2 Sonali P. Gunawardhana M.P.H., J.D., LL.M. Regulatory Counsel Food and Drug Administration Center for Devices and Radiological Health Office of Compliance Division of Bioresearch Monitoring
3 Disclaimer The contents of this presentation are my own, and do not necessarily reflect the views and/or policies of the Food and Drug Administration or its staff as per 21 CFR
4 Device Clinical Research Regulations 21 CFR 50: Protection of Human Subjects 21 CFR 54: Financial Disclosure 21 CFR 56: Institutional Review Boards 21 CFR 58: Good Laboratory Practice 21 CFR 812: Investigational Device Exemptions
5 CDRH BIMO INSPECTIONS Fiscal Years FY05 FY06 FY07 FY08 FY09
6 CDRH BIMO INSPECTIONS Fiscal Years Entity Sponsor CI IRB GLP
7 FY09 Investigator Deficiencies Follow investigational plan, investigator agreement, or protocol Document case hx/device exposure Obtain adequate informed consent Record and report protocol deviations Control of investigational device Report UADEs
8 FY09 Sponsor Deficiencies Monitor study Secure investigator compliance Obtain signed Investigator Agreement Provide information to properly conduct study Maintain current investigator list Inform investigators, FDA, or IRB
9 Sponsor-Investigator Inspections 31 Inspections of Sponsor- Investigators performed during FY 2008 and Warning Letters Issued = 35%
10 Inspection Classification 2, 6% 13, 42% NAI VAI OAI 16, 52% N = 31
11 Most Frequent Investigator Violations 9/11 Failure to follow investigational plan & FDA regs 8/11 Failure to maintain records 7/11 Failure to obtain informed consent in accordance with Part 50
12 Most IMPORTANT Violations Overall IDE Violations Failure to submit IDE [812.20] Failure to submit IDE supplement [812.35(a)] Monitoring Violations Failure to ensure proper monitoring [812.40] *10/11 Warning Letters had one, or both of these violations
13 Compliance Tools Untitled/Warning letter Re-inspection Informal conference 3rd party audits Rejection of site data Disqualification CI, IRB, or GLP Invoke Application Integrity Policy Revoke marketing permit Civil Money Penalties Seizure Injunction Prosecution
14 CDRH BIMO Warning Letters GLP IRB Sponsor CI FY05 FY06 FY07 FY08 FY09
15 Example Of An Inadequate Response: You enrolled and performed study surgery on at least eight subjects prior to IRB approval.
16 Example Of An Inadequate Response: 20 out of 25 subjects Case Report Forms (CRFs) were incomplete because information needed to determine study eligibility were missing and not available in source documents.
17 Example Of An Inadequate Response: Failure to adequately supervise the conduct of the study.
18 Example Of An Inadequate Response: Failure to properly monitor the study.
19 Example Of An Inadequate Response: Failure to conduct the study in accordance with the investigational plan.
20 Notice Of Initiation Of Disqualification Proceedings And Opportunity To Explain Applies to Clinical Investigators Some clinical investigators may have already received a Warning Letter but in some cases violations discovered on the first inspection are serious enough for the Center to issue the NIDPOE.
21 Disqualification Of Clinical Investigators A NIDPOE letter informs the recipient clinical investigator that FDA is initiating an administrative proceeding to determine whether the clinical investigator should be disqualified from receiving investigational products pursuant to the Food and Drug Administration's regulations. Generally, FDA issues a NIDPOE letter when it believes it has evidence that the clinical investigator repeatedly or deliberately violated FDA's regulations governing the proper conduct of clinical studies involving investigational products or submitted false information to the sponsor.
22 Notice Of Initiation Of Disqualification Proceedings And Opportunity To Explain Consent Agreements List specific responsibilities of the Clinical Investigator in terms of coming into compliance. Can last for a specific amount of time or can be an agreement the disqualification is permanent. Can be viewed as a tool to bring the Clinical Investigator into compliance which in turn serves as a way to educate the Clinical Investigator as to their regulatory responsibility for the current and future clinical trials.
23 Notice Of Initiation Of Disqualification Proceedings And Opportunity To Explain What does disqualification mean for the clinical investigator? Their name is added to a list on the FDA website that indicates that they are disqualified from participation in any type of clinical trial. Generally it means that they have incurred legal fees and it can open them up to more eminent liability. Some might feel that it has had a negative impact on their reputations.
24 Notice Of Initiation Of Disqualification Proceedings And Opportunity To Explain What does disqualification mean for the Sponsor? The data from the disqualified clinical site can not be used in their submission. (Monetary and Ethical considerations) Sponsor is responsible for oversight of all clinical investigators so there might be some serious issues in terms of monitoring which can lead to further regulatory action.
25 References CDRH Homepage CDRH Learn Device Advice Notice of Initiation of Disqualification Proceedings and Opportunity to Explain ngroom/ucm htm
26 Contact Information Sonali P. Gunawardhana, M.P.H., J.D., LL.M. Regulatory Counsel Office of Compliance Division of Bioresearch Monitoring Center for Devices and Radiological Health U.S. Food and Drug Administration New Hampshire Ave. Building 66, Room 3452 Silver Spring, MD Phone: (301) Fax: (301)
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS Food and Drug Administration Center for Devices and Radiological Health Office of Compliance Division of Bioresearch Monitoring Doreen Kezer,
More informationBIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
More informationFDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
More informationSolutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSolutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for
More informationWARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Charles J. Coté, M.D. Ref: 09-HFD-45-02-04
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More information: study utilizing trieib)(4) b)(4) I I""-", _
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EXPRESS Sarah H. Lisanby, M.D. 1051
More informationHow to Prepare for Federal Inspections and What to Expect
How to Prepare for Federal Inspections and What to Expect Jennifer A. Graf Tufts Medical Center Tufts University Health Sciences Director of IRB Operations Originally presented at the February 2011 Society
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationWARNING LETTER. an both of which were sponsored by. (formerly ). The products
g5~5s c Public Health Service ' SLRV7CLS r r f+ ~1Mr~la DEPARTMENT OF HEALTH & HUMAN SERVICES DEC 2 1 2005 Food and Drug Administration 9200 Corporate Blvd. Rockville, Maryland 20850 WARNING LETTER Via
More informationDEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield
More informationChapter 48 - Bioresearch Monitoring
COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes
More informationInspections and Study Monitoring
Inspections and Study Monitoring IRB Education Series 2006 Presentation may only be reused or reprinted with written permission from the Tufts-New England Medical Center/Tufts University IRB office. Audits
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationEssential Documents It s Not Just a Binder!
Essential Documents It s Not Just a Binder! Kelly Unsworth, MS, CCRC, CIP Director of Research Education & Training Office for Human Subject Protection SCORE June 5, 2014 But What percentage of 2014 (to
More informationFDA s Clinical Trial Inspections in China Including FDA Overall Goals
FDA s Clinical Trial Inspections in China Including FDA Overall Goals Prepared for You by Barbara Kephart Immel, President, Immel Resources LLC 2013, Immel Resources LLC 1 Overview Budget China Initiative
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationWARNING LETTER VIA FEDERAL EXPRES S
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman
More informationHealthcare Facility Regulation
Healthcare Facility Regulation October 21, 2016 Presented by Melanie Simon Division Chief 0 Our Mission HFR is committed to protecting Georgia s health care consumers and ensuring the quality of health
More information+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS
+,*,s WC, ~ *4+ S* DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service, % %,+ 747 +,m 7 Food and Drug Administration 5 Jg FEDERAL EXPRESS 2088 Gaither Road Rockville MD 20850 yw ~ ~ & 4 DEC 21997
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE) LETTER
DEPARTMENT OF HFM3-H & HWMAN SERVICES Public Health Service SEP 3 0 20()4 Food and Drug Admmistration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850 NOTICE OF INITIATION
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More information... f%odand DrugAdministration via Federal Express 2098 Gaither Road
~ S-C(,* #+ % f $ s 5 G += > DIZPARTMENT OF JjIEALTH & HUMAN SJZRVICES Public Health Sewice c I 176 T+) f%odand DrugAdministration via Federal Express 2098 Gaither Road RockviUe MD 20850 WARNING LETTER
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationRecord or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;
TEXAS HEALTH RESOUCES Table 17-III. Record Retention Schedule Human Subject Research Records and Documents Approved by THR System Performance Council (SPC): 19 January 2010 Effective Date: October 14,
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationWARNING LETTER. Dear Dr. Wright : DEPARTMENT OF HEALTH & HUMAN SERVICES CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Richard A. Wright. M.D. Ref: 09-HFD-45-02-0
More informationNotice of Initiation of Disqualification Proceeding And Opportunity to Explai n
NS-71- DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Center for Biologics Evaluation an d Research 1401 Rockville Pike Rockville MD 20852-1448 Notice of Initiation of Disqualification
More informationThe HIPAA Privacy Rule and Research: An Overview
The HIPAA Privacy Rule and Research: An Overview Joy Pritts, JD Research Associate Professor Health Policy Institute Georgetown University jlp@georgetown.edu 1 Topics HIPAA Background Overview of Privacy
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationCLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES
CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES OVERVIEW In response to public health concerns over largely unregulated laboratory services, Congress enacted
More informationEXEMPT RESEARCH. 1. Overview
EXEMPT RESEARCH 1. Overview Research involving human subjects may be exempt from federal regulations requiring IRB review. The Ohio State University (HRPP) is responsible for determining whether research
More informationHIPAA & Research Overview for the Privacy Board March 22, UAMS HIPAA Office Vera M. Chenault, JD
HIPAA & Research Overview for the Privacy Board March 22, 2011 UAMS HIPAA Office Vera M. Chenault, JD The Privacy Board - YOU HIPAA Privacy Rule establishes the requirements for membership and role of
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationAn Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule
An Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule SOT: Regulatory and Safety Evaluation Specialty Section Webinar September 29, 2017 Mark Seaton, Ph.D.,
More information% *++V,m Food and Drug Administration WARNING LETTER
,U -, /G?iz--f -p=y( / DEPARTMENT f #,twcttti 6+ -%,,, Jg OF HEALTH & HUMAN SERVICES Public Health Sewice s * 5 (?-Lx/b% n % *++V,m 7 ~~g~ Food and Drug Administration FEDERAL EXPRESS 2088 Gaither Road
More informationVia Federal Express IVARNING LETTER
DEPARTblENT OF HEALTH & HUMAN SERVICES Public Health Serwce NW - 7 2003 Food and Drug Admmistratron Center for Devices and Radiological Health 2098 Galther Road RockwIle. Maryland 20850 Via Federal Express
More informationLaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner
More informationADVANCED PLASTIC SURGERY, PLLC. NOTICE OF PRIVACY PRACTICES
Effective Date: July 1 st 2013 ADVANCED PLASTIC SURGERY, PLLC. NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO
More informationToward Greater Scientific Rigor
Toward Greater Scientific Rigor Good Clinical Practice (GCP) A NEW REQUIREMENT! The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork The requirement:
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationDRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008
Draft Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers DRAFT GUIDANCE This guidance
More informationPreparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova
Preparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova Disclosures The speakers have no relevant financial and non-financial relationships to disclose. The
More information. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and
* %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal
More informationREQUEST FOR PROPOSALS: AUDIT SERVICES. Issue Date: February 13 th, Due Date: March 22 nd, 2017
REQUEST FOR PROPOSALS: AUDIT SERVICES Issue Date: February 13 th, 2017 Due Date: March 22 nd, 2017 In order to be considered, proposals must be signed and returned via email to rtan@wested.org by noon
More informationHuman Subject Regulations Decision Charts
Human Subject Regulations Decision Charts September 24, 2004 The Office for Human Research Protections (OHRP) provides the following graphic aids as a guide for institutional review boards (IRBs), investigators,
More information1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements
Information for Investigators: Headquarters, U.S. Special Operations Command Human Research Protection Office (HRPO) Human Research Protections Regulatory Requirements 1. Department of Defense (DoD) Human
More informationThe SOP applies to all human subject research falling under the purview of the University of Missouri Institutional Review Board.
Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Informed Consent Types and Elements Informed Consent Types and Elements Effective Date: December 12, 2005 Original
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control
General Administration GA 104.00 STANDARD OPERATING PROCEDURE FOR Document Development and Change Control Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval:
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationGuidance for Institutional Review Boards, Clinical Investigators, and Sponsors. Exception from Informed Consent Requirements for Emergency Research
Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research U.S. Department of Health and Human Services Food and
More informationANNUAL POST-EMPLOYMENT CERTIFICATION & NOTIFICATION TO SENIOR OFFICIALS OF POST-GOVERNMENT EMPLOYMENT RESTRICTIONS UNDER 18 U.S.C.
Certification: Because you are a member of the Department of Defense who files a public financial disclosure report (SF 278), DoD 5500.7-R, Joint Ethics Regulation (JER), requires you to certify each year
More informationDocument Title: Informed Consent for Research Studies
Document Title: Informed Consent for Research Studies Document Number: SOP003 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationc+!!!! # -) NW DEPARTMENT OF HEALTH& HUMAN SERVICES Food and Drug Administration CBER Certified Mail Return Receipt Requested
c+!!!! # -) i v L DEPARTMENT OF HEALTH& HUMAN SERVICES Food and Drug Administration CBER-01-006 WI% Center for Biologics Evaluation and Research 1401 Rockville Pike Rockville MD 20852-1448 NW 302000 WARNING
More informationEffective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.
TITLE: Standard Operating Procedure (SOP) External Inspections or Audits NUMBER: NSHA REB-SOP-9-002 Effective Date: April 2014 Revision: September 29, 2017 Applies To: Executive Chair, Co-Chairs, NSHA
More informationDocument issued on: July 8, 2010
Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and Food and Drug Administration Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers Document
More informationPatient Consent Form
Alexander Raskin, M.D., Q.M.E. Assistant Clinical Professor UCLA School of Medicine ORTHOPEDIC SURGERY SPORTS MEDICINE ARTHROSCOPY 16311 Ventura Blvd., Suite 1150, Encino, CA 91436 T (818) 788-ORTHO (6784)
More informationPage 2- Alan Rapoport, M.D.
~ I^ 1 ) ~~ ~~ ls sr~ L DEPA RTMENT OF HEALTH & HUMAN SERViCES Public Health Se rvice J~T~ ;awyicf,{,~-
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationSenior Care Pharmacy Wichita
Senior Care Pharmacy Wichita 1402 S.RIDGE ROAD WICHITA, KS, 67209 Phone: 316-945-7455 Fax: 316-945-7457 Contact:- Carol Parsons Dear patient/responsible party, Effective immediately, each patient/responsible
More informationThe Queen s Medical Center HIPAA Training Packet for Researchers
The Queen s Medical Center HIPAA Training Packet for Researchers 1 The Queen s Medical Center HIPAA Training Packet for Researchers Table of Contents Overview of HIPAA and Research 3 Penalties for violations
More informationFOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM
FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7348.810 CHAPTER 48 Bioresearch Monitoring SUBJECT: SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS REVISION: IMPLEMENTATION
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationBASSIN CENTER FOR PLASTIC SURGERY. Dr. Roger Bassin NOTICE OF PRIVACY PRACTICES
BASSIN CENTER FOR PLASTIC SURGERY Dr. Roger Bassin NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED, AND HOW YOU CAN GET ACCESS TO THIS INFORMATION.
More informationTOWN AUDITING SERVICES
REQUEST FOR PROPOSAL TOWN AUDITING SERVICES TOWN OF LONGMEADOW MASSACHUSETTS Saved as: RPF Acct Auditing Services FY 12-14 03/1/11 TOWN OF LONGMEADOW REQUEST FOR PROPOSALS FOR AUDITING SERVICES The Town
More informationAudits, Administrative Reviews, & Serious Deficiencies
Audits, Administrative Reviews, & Serious Deficiencies 20 Contents Section A Audits...20.2 Section B Administrative Reviews...20.3 Entrance Interview...20.3 Records Review...20.3 Meal Observation...20.5
More informationA self-assessment for GxP and HIPAA concerns
WHITE PAPER IS YOUR ORGANIZATION AT RISK? A self-assessment for GxP and HIPAA concerns MDDX RESEARCH & INFORMATICS 58 California St, Floor 6 San Francisco, California 9 T (8) -MDDX F (866) 8-696 info@mddx.com
More informationLondonderry Finance Department
Londonderry Finance Department 268 B Mammoth Road Londonderry, NH 03053 (603) 432-1100 Douglas Smith, Finance Director email: dsmith@londonderrynh.org Justin Campo, Senior Accountant Email: jcampo@londonderrynh.org
More informationLifeBridge Health HIPAA Policy 4. Uses of Protected Health Information for Research
LifeBridge Health HIPAA Policy 4 Uses of Protected Health Information for Research This Policy contains the following Sections: I. Policy II. III. IV. Definitions Applicability Procedures A. Individual
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationSelf-Monitoring Tool
This form is designed for research personnel to use to assess their compliance with TTUHSC El Paso IRB policies and procedures, and federal regulations and guidance governing research with human subjects,
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationThe Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.
The Clinical Research Center Research Practice Manual Guideline for Study Document and Data Handling RPG-08 Purpose Guideline This Guideline provides functional definitions for common data management terms;
More informationPrivacy Rule Overview
Privacy Rule Overview Protected Health Information (PHI) is private information that is subject to special treatment under the HIPAA Privacy Regulations. PHI can only be used or disclosed in research if
More informationI. Preamble: II. Parties:
I. Preamble: MEMORANDUM OF UNDERSTANDING BETWEEN THE FEDERAL COMMUNICATIONS COMMISSION AND THE FOOD AND DRUG ADMINISTRATION CENTER FOR DEVICES AND RADIOLOGICAL HEALTH The Food and Drug Administration (FDA)
More informationSCHOOL OF PUBLIC HEALTH. HIPAA Privacy Training
SCHOOL OF PUBLIC HEALTH HIPAA Privacy Training Public Health and HIPAA This presentation will address the HIPAA Privacy regulations as they effect the activities of the School of Public Health. It is imperative
More informationBE-595M Homework Assignment Due: 3/3/08
BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures
More informationNotice of Privacy Practices for Protected Health Information
Notice of Privacy Practices for Protected Health Information This notice describes how medical information about you may be used and disclosed and how you can get access to this information. Please review
More informationRhode Island Commerce Corporation. Rules and Regulations for the Innovation Voucher Program
Rules and Regulations for the Innovation Voucher Program Effective Date: November 25, 2015 Table of Contents Page Rule 1. Purpose.... 2 Rule 2. Authority.... 2 Rule 3. Scope.... 2 Rule 4. Severability....
More informationClinical Research Seminar
Clinical Research Seminar HOW TO DEVELOP A CORRECTIVE AND PREVENTIVE ACTION PLAN (THAT EVEN THE IRB AND FDA WILL LOVE) April 11, 2018 Fiona Rice, MPH Human Research Quality Manager fionar@bu.edu Mary-Tara
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationCompliance Policy C-FMS Clinical Research Project Approval Application
Internal Use Only: Business Unit: Fresenius Medical Services Region: RVP: Area Manager: Facility # Compliance Policy C-FMS-009.2 of Investigator or Study Coordinator completes the following: Facility Name
More information4 ( DEPARTMENT OF HEALTH& HUMAN SERVICES Public Health Service
4 ( DEPARTMENT OF HEALTH& HUMAN SERVICES Public Health Service X+m CBER40-018 0 ] =-?-7/7 Food and Drug Administration Center for Biologics Evacuation and Research 1401 Rockville Pike Rockville MD 20852-1448
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)
Replaces previous version 203.01: 01 July 2014 Study Start-Up SS 203.01 STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature
More informationTown of Derry, NH REQUEST FOR PROPOSALS PROFESSIONAL MUNICIPAL AUDITING SERVICES
Town of Derry, NH Office of the Finance Department Susan A. Hickey Chief Financial Officer susanhickey@derrynh.org REQUEST FOR PROPOSALS PROFESSIONAL MUNICIPAL AUDITING SERVICES The Town of Derry, New
More information